Deutsche Bank set a €133.00 ($154.65) price target on MorphoSys (ETR:MOR) in a research note released on Thursday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

MOR has been the topic of a number of other reports. Goldman Sachs Group set a €114.00 ($132.56) price target on shares of MorphoSys and gave the company a neutral rating in a research report on Wednesday, August 7th. Independent Research set a €96.00 ($111.63) price objective on shares of MorphoSys and gave the stock a neutral rating in a research report on Thursday, July 4th. Royal Bank of Canada set a €65.00 ($75.58) price objective on shares of MorphoSys and gave the stock a sell rating in a research report on Monday, June 24th. JPMorgan Chase & Co. set a €120.00 ($139.53) price objective on shares of MorphoSys and gave the stock a buy rating in a research report on Wednesday, August 7th. Finally, Berenberg Bank set a €150.00 ($174.42) price objective on shares of MorphoSys and gave the stock a buy rating in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of €113.56 ($132.04).

MOR opened at €111.00 ($129.07) on Thursday. The company has a debt-to-equity ratio of 8.61, a current ratio of 7.62 and a quick ratio of 7.40. The firm’s 50-day moving average price is €96.61. MorphoSys has a fifty-two week low of €76.45 ($88.90) and a fifty-two week high of €114.60 ($133.26). The company has a market capitalization of $3.50 billion and a price-to-earnings ratio of -84.03.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

See Also: Support Level

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.